Overview

Galenica AG reported a robust financial performance for the fiscal year 2025, surpassing market expectations across revenue, profitability, and operating efficiency. The company announced an upward revision of its mid‑term guidance, reinforcing confidence in its growth strategy.

2025 Financial Highlights

  • Revenue

  • Total sales increased by 5.5 % to CHF 4 135.6 million.

  • Growth was driven by all operating segments, including pharmacy retail, wholesale distribution, home care, and diagnostics.

  • Profitability

  • Adjusted EBIT rose by 11.3 % to CHF 234.8 million.

  • The improvement reflects higher sales volumes, cost efficiencies, and stronger margin performance across the business portfolio.

  • Operational Cash Flow

  • Targeted management of net working capital strengthened operating cash flow, supporting the company’s liquidity position.

Guidance for 2026 and Beyond

  • 2026 Sales Forecast

  • Galenica expects a revenue increase between 5 % and 7 %.

  • 2026 Adjusted EBIT Forecast

  • EBIT growth is projected at 6 % to 8 %.

  • Mid‑Term EBIT Outlook (up to 2027)

  • The company has lifted its adjusted EBIT guidance to CHF 270 million.

These forecasts incorporate the foundations laid in 2025 for further expansion in home care and diagnostics, as well as the efficiencies realized through modernized wholesale systems.

Segment‑Level Contributions

SegmentKey Drivers
PharmacyEnhanced basic care through expanded consultation services
WholesaleImplementation of modern logistics and information systems
Home Care & DiagnosticsStrategic initiatives positioned for future growth

Market Context

  • Share Price (08‑Mar‑2026): CHF 93.9
  • Market Capitalisation: CHF 4.679 billion
  • Price‑to‑Earnings Ratio: 24.276

The company’s performance aligns with its long‑term growth strategy and positions it well for continued expansion in the Swiss health‑care market.